BIOPHTA

Executive Summary

BIOPHTA is a French biotech company founded in 2020 and headquartered in Paris, specializing in a novel drug delivery platform for ophthalmology. The company's lead technology is a self-administered, non-invasive sustained-release ocular insert—a dry mini-tablet that gels upon contact with the eye, providing continuous microdosing of medication for up to one week. This approach aims to address the significant unmet need in ocular treatment adherence and efficacy, offering a patient-friendly alternative to frequent eye drops or invasive injections. The platform has the potential to improve outcomes for chronic eye conditions such as glaucoma, dry eye disease, and post-surgical inflammation. As a privately held, early-stage company, BIOPHTA is likely focused on advancing its platform through preclinical studies and initial clinical trials. The company has not disclosed its total funding or valuation, but its innovative approach positions it as a potential target for partnerships or acquisitions by larger ophthalmic players. Key upcoming catalysts include the completion of pivotal preclinical studies, potential Series A financing to support first-in-human trials, and the announcement of a strategic collaboration. The company's success hinges on demonstrating the safety and efficacy of its delivery system in humans.

Upcoming Catalysts (preview)

• Q4 2026Completion of preclinical efficacy study65% success
• Q1 2027Series A financing round50% success
• Q3 2027First-in-human trial initiation40% success